Press Release
Abbott To Preview New CELL-DYN® Emerald™ Hematology Instrument
CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to
Mid-Sized Laboratories
July 28, 2008
Washington, D.C. — Abbott (NYSE: ABT)
will preview an upcoming addition to the CELL-DYN® family of hematology
instruments, the Emerald™, at the American Association of Clinical Chemistry
(AACC) Annual Meeting this week. The Emerald is designed to be a valuable tool
for performing complete blood counts (CBCs) - a test frequently ordered by
doctors to assess a patient's overall health and to screen for a variety of
disorders such as anemia and infection. The Emerald has the ability to complete
CBC results in 60 seconds and report results in easy-to-read histograms
representing white blood cells, red blood cells and platelets.
Expected to be available in the United States by the end of the year,
subject to regulatory clearance, the Emerald will expand Abbott's hematology
platform by offering a premium, robust low-volume solution for small to
mid-sized clinical laboratories. Enhanced technology combined with intuitive
software and onboard reagents enable the Emerald to offer reliable performance
while promoting faster and simpler data entry.
As low to medium-volume hospital laboratories and clinics continue to seek
greater efficiency under tight space limitations, the Emerald is expected to
deliver reliable, productivity-enhancing performance in a small footprint.
The AACC Annual Meeting is a global meeting that attracts nearly 20,000
attendees from more than 100 countries. The Emerald is on display in Abbott's
AACC exhibit booth (No. 1507).
About CELL-DYN
Abbott's CELL-DYN family of hematology instruments is well known for its
efficiency and ability to provide fast access to patient results. Instruments
range from larger analyzers that process a high number of patient samples to
smaller instruments designed for medium and small-volume facilities. Besides
supplying standard CBC results, some instruments have additional features to
aid in the evaluation of more complex disease states or infections including
cancer, HIV and a variety of anemias.
About Abbott's Diagnostics Businesses
Abbott is a global leader in in vitro diagnostics and offers a broad
range of innovative instrument systems and tests for hospitals, reference labs,
molecular labs, blood banks, physician offices and clinics. With more than
65,000 customers in more than 100 countries, Abbott's diagnostic products offer
customers automation, convenience, bedside testing, cost effectiveness and
flexibility. Abbott has helped transform the practice of medical diagnosis from
an art to a science through the company's commitment to improving patient care
and lowering costs. Abbott's history is filled with examples of first-of-a-kind
diagnostic products and significant technological and research
advancements.
About Abbott
Abbott (NYSE: ABT)
is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company employs more than
68,000 people and markets its products in more than 130 countries.
Media:
Don Braakman |
(847) 937-0080 |
